United Therapeutics Corporation (UTHR) compared with its closest peers (BMRN, AMRX, ALNY, RPRX, SRPT): P/E 16.6 vs industry 17.2. Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
BioMarin Pharmaceutical, Amneal Pharmaceuticals, Alnylam Pharmaceuticals, Royalty Pharma, Sarepta Therapeutics, PTC Therapeutics, Organon, Phibro Animal Health, Indivior Pharmaceuticals and Lakefront Biotherapeutics share United Therapeutics's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| BioMarin Pharmaceutical Inc. (BMRN) | $12.59B | 172.6 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $5.67B | 36.1 |
| Alnylam Pharmaceuticals, Inc. (ALNY) | $31.52B | 108.0 |
| Royalty Pharma plc (RPRX) | $34.14B | 41.3 |
| Sarepta Therapeutics, Inc. (SRPT) | $1.91B | -3.0 |
| PTC Therapeutics, Inc. (PTCT) | $5.93B | 9.8 |
| Organon & Co. (OGN) | $3.61B | 17.3 |
| Phibro Animal Health Corporation (PAHC) | $1.45B | 15.2 |
| Indivior Pharmaceuticals Inc (INDV) | $4.27B | 12.5 |
| Lakefront Biotherapeutics NV (LKFT) | $1.93B | 6.0 |
| Stock P/E | 16.6 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| vs Sector | -23.6% |
| vs Industry | -3.3% |
UTHR overview · UTHR earnings · UTHR financials · UTHR KPIs · UTHR documents · UTHR ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.